January 22: The Week in Cancer News
African American men are more likely to feel regret about prostate cancer treatment decisions, and more news of the...
Progress Against Cancer
African American men are more likely to feel regret about prostate cancer treatment decisions, and more news of the...
The FDA approved the first once-a-day pill to lower the levels of testosterone in certain patients with prostate cancer....
The FDA granted approval to expand the use of a minimally invasive biomarker test to identify certain patients with ovarian,...
Prostate cancer is the second most diagnosed cancer among men in the United States, and non-Hispanic black men bear a...
Metastatic prostate cancer incidence rose after changes to prostate cancer screening guidelines.
The FDA has expanded the use of the PARP-targeted therapeutic olaparib to include the treatment of certain patients with...
The FDA has expanded the use of a molecularly targeted therapeutic to include the treatment of certain patients with...
Using an older method of prostate biopsy together with MRI-targeted biopsy more accurately diagnoses prostate cancer than either method...
A new antihormone agent darolutamide (Nubeqa) provides men with nonmetastatic prostate cancer a third option to control the disease...
A recent study found that exposure to World Trade Center dust may alter inflammatory pathways, leading to the progression...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 47,000 members worldwide drive progress against cancer.
Donate Now